Biocon Biologics’ Yesafili to enter US market, after agreement with Regeneron
Spread the loveBiocon Biologics has reached a settlement with Regeneron, allowing the launch of Yesafili, its biosimilar eye drug, in the US by the second half of 2026. Approved by … Read More